Plus Therapeutics: A Year of Promise and Progress in Central Nervous System Cancers
HOUSTON, March 27, 2025 – Plus Therapeutics, Inc. (Nasdaq: PSTV), a pioneering clinical-stage pharmaceutical company, recently unveiled its financial results for the fourth quarter and full year ended December 31, 2024. The company, which specializes in developing targeted radiotherapeutics for central nervous system (CNS) cancers using advanced platform technologies, reported significant progress in its two most advanced programs, REYOBIQ (plus estradiol iodine-131) and PTX-19. In the words of Marc H. Caron, President and CEO of Plus Therapeutics:
“Over the last twelve months, Plus has reported very promising safety and efficacy data for our lead drug REYOBIQ administered in our two most advanced CNS cancer programs,”
REYOBIQ: A New Hope for CNS Cancer Patients
The first program, REYOBIQ, focuses on the treatment of recurrent glioblastoma multiforme (rGBM), the most common and aggressive form of brain cancer. In a Phase 1/2 trial, REYOBIQ demonstrated impressive results, extending the median progression-free survival (PFS) by 2.5 months compared to the historical standard of care. Furthermore, the treatment was shown to be safe and well-tolerated by patients.
PTX-19: Targeting a New Frontier in CNS Cancer Treatment
The second program, PTX-19, targets the treatment of pediatric brainstem glioma, a rare and devastating form of CNS cancer. In preclinical studies, PTX-19 demonstrated the ability to penetrate the blood-brain barrier and selectively target tumor cells, offering hope for patients with limited treatment options.
Recent and Upcoming Business Highlights
In addition to these promising developments, Plus Therapeutics has also recently:
- Announced the appointment of Dr. Mary Lauby as Chief Medical Officer, bringing extensive experience in CNS oncology and radiotherapeutics
- Secured a $50 million equity investment to support the advancement of its pipeline
- Initiated a Phase 2 trial for REYOBIQ in rGBM, with top-line data expected in 2026
The Impact on Individuals and the World
For those battling CNS cancers, the progress made by Plus Therapeutics represents a significant step forward. With promising data from both REYOBIQ and PTX-19, Plus is poised to offer new hope to patients who have exhausted traditional treatment options. The potential for increased survival and improved quality of life is a cause for celebration.
Beyond individual patients, the impact of Plus Therapeutics’ advancements extends to the broader world. The development of targeted radiotherapeutics for CNS cancers has the potential to revolutionize the field, offering more effective and less invasive treatment options. Furthermore, the success of Plus Therapeutics could pave the way for other companies to invest in and innovate within the CNS oncology space.
Conclusion
In conclusion, Plus Therapeutics’ financial results for the fourth quarter and full year ended December 31, 2024, serve as a testament to the company’s commitment to advancing the treatment of CNS cancers. With promising data from its lead drug, REYOBIQ, and its second program, PTX-19, Plus Therapeutics is poised to make a significant impact on the lives of patients and the future of CNS oncology research.
